Investigating how CD38 affects multiple myeloma treatment outcomes
Exploring CD38 molecular biology and imaging in multiple myeloma pathogenesis
This study is looking at how a protein called CD38 affects the success of antibody treatments for people with multiple myeloma, to help doctors better choose the right therapies for patients who have had their cancer come back or haven't responded to previous treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10840483 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of CD38, a protein found on multiple myeloma cells, in the effectiveness of antibody-based therapies. By examining how CD38 functions and its enzymatic activity, the study aims to identify why some patients respond well to treatments while others do not. The research involves analyzing patient samples and exploring the relationship between CD38 activity and treatment outcomes. Ultimately, the goal is to improve therapy selection for patients with relapsed and refractory multiple myeloma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with relapsed or refractory multiple myeloma who are undergoing treatment.
Not a fit: Patients with early-stage multiple myeloma or those who are not receiving antibody-based therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment options for patients with multiple myeloma.
How similar studies have performed: Previous research has shown promising results with CD38-targeted therapies in multiple myeloma, indicating that this approach has potential for further exploration.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Shokeen, Monica — Washington University
- Study coordinator: Shokeen, Monica
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.